CRDF Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
171.0K
+64.4%
104.0K
+153.7%
41.0K
-83.1%
243.0K
+102.5%
120.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
171.0K
+64.4%
104.0K
+153.7%
41.0K
-83.1%
243.0K
+102.5%
120.0K
Operating Expenses
9.4M
-3.4%
9.7M
-24.6%
12.9M
+59.7%
8.1M
-33.3%
12.1M
R&D
5.0M
-15.0%
5.9M
-12.6%
6.8M
+33.3%
5.1M
-38.1%
8.2M
SG&A
4.4M
+14.6%
3.8M
-37.9%
6.1M
+104.5%
3.0M
-23.1%
3.9M
Operating Income
-9219000
+4.1%
-9615000
+25.2%
-12850000
-64.2%
-7827000
+34.6%
-11974000
EBITDA
-9131000
+4.2%
-9528000
+25.3%
-12763000
-64.9%
-7739000
+34.9%
-11885000
Net Income
-8857000
+4.1%
-9232000
+25.2%
-12345000
-71.1%
-7216000
+35.9%
-11258000
EPS (Basic)
$-0.12
+14.3%
$-0.14
+22.2%
$-0.18
-63.6%
$-0.11
+35.3%
$-0.17
EPS (Diluted)
$-0.12
+14.3%
$-0.14
+22.2%
$-0.18
-63.6%
$-0.11
+35.3%
$-0.17
Shares (Diluted)
76.2M
+11.4%
68.4M
+0.1%
68.3M
+1.4%
67.4M
+0.8%
66.9M
Cardiff Oncology (CRDF) — Financials